论文部分内容阅读
日本肺癌学会总会(JLCS)于1987年11月5～6日在日本大阪市召开第28届学术年会。交流论文634篇,出席人数1,800人,中国代表8人。大会特邀美国肺癌研究协作组主席,加利福尼亚洲大学胸外科教授Holmes博士作专题讲演,论述晚期肺癌外科辅助治疗(Surgical Adjurant Thera-py)的新研究和新观点。现作一简介。 晚期肺癌的化学治疗效果远不如乳腺癌、小细胞肺癌、睾丸癌和其它实体瘤那样明显。以往一些研究报告很难确定化疗的效应率,致使一些人对肺癌的化疗产生怀疑。然而,化疗药物联合应用的发展,特别是顺氯氨铂的应用,使晚期转移性非小细胞癌获得30～40％的效应率,最常用的化疗方案包括CAP(环磷酰胺+阿霉素+顺铂)、顺铂+
The Japan Lung Cancer Association (JLCS) held its 28th academic annual meeting in Osaka City, Japan from November 5th to 6th, 1987. 634 papers were exchanged, with 1,800 attendees and 8 Chinese representatives. The conference invited the chairperson of the US Lung Cancer Research Collaboration Group and Professor Holmes, professor of thoracic surgery at the University of California, California, to give a special lecture on the new research and new ideas of surgical adjuvant therapy for advanced lung cancer (Surgical Adjurant Thera-py). Now make a brief introduction. The efficacy of chemotherapy for advanced lung cancer is far less pronounced than for breast cancer, small cell lung cancer, testicular cancer, and other solid tumors. In previous studies, it was difficult to determine the effect rate of chemotherapy, causing some people to doubt the chemotherapy of lung cancer. However, the development of combined use of chemotherapeutic drugs, especially the use of cisplatin, has resulted in a 30 to 40% effect rate for advanced metastatic non-small cell carcinoma. The most commonly used chemotherapy regimens include CAP (cyclophosphamide + adriamycin). + Cisplatin), Cisplatin +